Who we are
“Personalis” is Latin for “Personal.” Human genome sequences contain substantial personal medical information, which can be useful either for research or, increasingly, clinical practice. Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.
The Personalis ACE Exome and Transcriptome Technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenviroment for immuno-oncology applications including neoantigen prediction and mutational burden assessment. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more.
Our founding story
In mid-2009, Illumina® introduced its Individual Genome Sequencing service. Mr. West (now our CEO), his wife and two children signed up and were the first family of four to be sequenced by Illumina. Mr. West’s genome data was made public by submission to NCBI, and he joined the Harvard Personal Genome project. At about that time, a team at Stanford published a landmark paper “Clinical Assessment Incorporating a Personal Genome” (Lancet, May 1, 2010). The Wests began collaboration with this Stanford team to apply those techniques to their genome data, and to advance the techniques by leveraging the power of a family data set. Initial results from this collaboration were published on-line in PLoS Genetics on Sept 15, 2011. Four Stanford faculty members led this effort:Dr. Euan Ashley, Dr. Atul Butte, Dr. Russ Altman, and Dr. Michael Snyder. Along with Mr. West, the Stanford team realized the demand for this type of analysis could grow exponentially – Personalis was founded.